Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Mar 22;63(6):665–670. doi: 10.1136/ard.2003.016386

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis

M Rudwaleit 1, J Listing 1, J Brandt 1, J Braun 1, J Sieper 1
PMCID: PMC1755042  PMID: 15037444

Abstract

Background: TNFα blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS).

Objective: To identify parameters predicting the clinical response to TNF blockers in AS.

Methods: Patients with active AS participated in two placebo controlled, randomised trials conducted in Germany with infliximab (n = 69) and etanercept (n = 30), respectively. For inclusion in either trial patients had to have high disease activity (BASDAI ⩾4) and a spinal pain score (numerical rating scale 0–10) ⩾4 despite treatment with NSAIDs. A major clinical response was defined as a 50% improvement of the initial BASDAI (BASDAI 50) after 12 weeks' treatment with active drug. Logistic regression likelihood ratio tests (univariate and multivariate), Student's t test, and χ2 tests were performed.

Results: Univariate analysis showed the following to be predictors of a major response (BASDAI 50) to treatment: shorter disease duration (p = 0.003); lower BASFI (p = 0.007); younger age (p = 0.009); raised ESR (p = 0.033); raised CRP (p = 0.035). After adjustment for disease duration, BASFI, ESR, and CRP, but not age, remained significantly associated. After adjustment for disease duration and for BASFI, ESR, CRP, and in addition, a higher BASDAI were significantly associated with response. The best multivariate model built by stepwise regression contained the covariables disease duration, BASFI, BASDAI, and CRP.

Conclusion: A shorter disease duration, younger age, and a lower BASFI are predictors of a major clinical response to TNF blockers in active AS. Raised CRP and a higher BASDAI may also be valuable predictors. These data need to be confirmed in further studies.

Full Text

The Full Text of this article is available as a PDF (129.0 KB).

Figure 1 .

Figure 1

Open in a new tab

Relationship between disease duration and proportion of patients (%) who achieved a BASDAI 50 response after 12 weeks. Here, patients (n = 99) were grouped into three blocks of disease duration (⩽10 years, 11–20 years, >20 years). Patients with shorter disease duration had a significantly higher chance of achieving BASDAI 50 than patients with longer disease duration (χ2 = 11.7; p = 0.003).

Figure 2 .

Figure 2

Open in a new tab

Relationship between functional status (BASFI) and proportion of patients (%) who achieved a BASDAI 50 response after 12 weeks. Patients (n = 99) were grouped into blocks of various BASFI scores. Patients with lower BASFI scores (that is, better functional status) had a significantly higher chance of achieving BASDAI 50 than patients with higher BASFI scores (that is, worse functional status) (χ2 = 8.2; p = 0.017).

Figure 3 .

Figure 3

Open in a new tab

Relationship between disease activity (BASDAI) and proportion of patients (%) who achieved a BASDAI 50 response after 12 weeks. Patients (n = 99) were grouped into blocks of various BASDAI scores. Patients with a BASDAI >5 had a significantly higher chance of achieving BASDAI 50 than patients with a BASDAI of 4–5 (OR = 3.8, 95% CI 1.2 to11.7; p = 0.024).

Figure 4 .

Figure 4

Open in a new tab

Probability of a BASDAI 50 response after 12 weeks depending on CRP levels at baseline and disease duration. The three curves were calculated by bivariate logistic regression analysis. They represent the expected probabilities of response for three selected levels of disease duration (5 years, 15 years, 25 years) and various levels of CRP.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. J., Baron G., van der Heijde D., Felson D. T., Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001 Aug;44(8):1876–1886. doi: 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  2. Bollow M., Enzweiler C., Taupitz M., Golder W., Hamm B., Sieper J., Braun J. Use of contrast enhanced magnetic resonance imaging to detect spinal inflammation in patients with spondyloarthritides. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S167–S174. [PubMed] [Google Scholar]
  3. Brandt J., Haibel H., Cornely D., Golder W., Gonzalez J., Reddig J., Thriene W., Sieper J., Braun J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000 Jun;43(6):1346–1352. doi: 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  4. Brandt J., Haibel H., Sieper J., Reddig J., Braun J. Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum. 2001 Dec;44(12):2936–2937. doi: 10.1002/1529-0131(200112)44:12<2936::aid-art483>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  5. Brandt J., Khariouzov A., Listing J., Haibel H., Sörensen H., Grassnickel L., Rudwaleit M., Sieper J., Braun J. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003 Jun;48(6):1667–1675. doi: 10.1002/art.11017. [DOI] [PubMed] [Google Scholar]
  6. Braun J., Baraliakos X., Golder W., Brandt J., Rudwaleit M., Listing J., Bollow M., Sieper J., Van Der Heijde D. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. 2003 Apr;48(4):1126–1136. doi: 10.1002/art.10883. [DOI] [PubMed] [Google Scholar]
  7. Braun J., Bollow M., Eggens U., König H., Distler A., Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum. 1994 Jul;37(7):1039–1045. doi: 10.1002/art.1780370709. [DOI] [PubMed] [Google Scholar]
  8. Braun J., Bollow M., Remlinger G., Eggens U., Rudwaleit M., Distler A., Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998 Jan;41(1):58–67. doi: 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  9. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187–1193. doi: 10.1016/s0140-6736(02)08215-6. [DOI] [PubMed] [Google Scholar]
  10. Braun J., Pham T., Sieper J., Davis J., van der Linden Sj, Dougados M., van der Heijde D., ASAS Working Group International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003 Sep;62(9):817–824. doi: 10.1136/ard.62.9.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Breban M., Vignon E., Claudepierre P., Devauchelle V., Wendling D., Lespessailles E., Euller-Ziegler L., Sibilia J., Perdriger A., Mezières M. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002 Nov;41(11):1280–1285. doi: 10.1093/rheumatology/41.11.1280. [DOI] [PubMed] [Google Scholar]
  12. Bresnihan Barry, Cunnane Gaye. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am. 2003 Feb;29(1):185–202. doi: 10.1016/s0889-857x(02)00101-1. [DOI] [PubMed] [Google Scholar]
  13. Calin A., Garrett S., Whitelock H., Kennedy L. G., O'Hea J., Mallorie P., Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994 Dec;21(12):2281–2285. [PubMed] [Google Scholar]
  14. Dougados M., Dijkmans B., Khan M., Maksymowych W., van der Linden Sj, Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis. 2002 Dec;61 (Suppl 3):iii40–iii50. doi: 10.1136/ard.61.suppl_3.iii40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Feldtkeller Ernst, Khan Muhammad Asim, van der Heijde Désirée, van der Linden Sjef, Braun Jürgen. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 2002 Sep 3;23(2):61–66. doi: 10.1007/s00296-002-0237-4. [DOI] [PubMed] [Google Scholar]
  16. Garrett S., Jenkinson T., Kennedy L. G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec;21(12):2286–2291. [PubMed] [Google Scholar]
  17. Gorman Jennifer D., Sack Kenneth E., Davis John C., Jr Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2;346(18):1349–1356. doi: 10.1056/NEJMoa012664. [DOI] [PubMed] [Google Scholar]
  18. Jenkinson T. R., Mallorie P. A., Whitelock H. C., Kennedy L. G., Garrett S. L., Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994 Sep;21(9):1694–1698. [PubMed] [Google Scholar]
  19. MacKay K., Mack C., Brophy S., Calin A. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum. 1998 Dec;41(12):2263–2270. doi: 10.1002/1529-0131(199812)41:12<2263::AID-ART23>3.0.CO;2-I. [DOI] [PubMed] [Google Scholar]
  20. Maksymowych Walter P., Jhangri Gian S., Lambert Robert G., Mallon Cathy, Buenviaje Heidi, Pedrycz Ewa, Luongo Rolfe, Russell Anthony S. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol. 2002 May;29(5):959–965. [PubMed] [Google Scholar]
  21. Marc V., Dromer C., Le Guennec P., Manelfe C., Fournie B. Magnetic resonance imaging and axial involvement in spondylarthropathies. Delineation of the spinal entheses. Rev Rhum Engl Ed. 1997 Jul-Sep;64(7-9):465–473. [PubMed] [Google Scholar]
  22. Marzo-Ortega H., McGonagle D., O'Connor P., Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. 2001 Sep;44(9):2112–2117. doi: 10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  23. Saraux A., Guedes C., Allain J., Devauchelle V., Valls I., Lamour A., Guillemin F., Youinou P., Le Goff P. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Société de Rhumatologie de l'Ouest. J Rheumatol. 1999 Dec;26(12):2622–2627. [PubMed] [Google Scholar]
  24. Sieper J., Braun J., Rudwaleit M., Boonen A., Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002 Dec;61 (Suppl 3):iii8–ii18. doi: 10.1136/ard.61.suppl_3.iii8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis. 2003 Feb;62(2):97–99. doi: 10.1136/ard.62.2.97. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES